Company profile
BridgeBio Pharma, Inc.
Pipeline5 assets
- AcoramidisAttruby / TTR (Transthyretin) / Small Molecule / Genetic diseaseEarly-Stage Variant Transthyretin Amyloidosis (ATTRv)Phase 3Under investigation
- BBP-418BBP-418 / FKRP / Small Molecule / Genetic disease; neuromuscularLimb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)Phase 3Investigational; FORTIFY interim analysis met endpoints
- EncaleretCASR / Small Molecule / Endocrine; genetic diseaseAutosomal Dominant Hypocalcemia Type 1 (ADH1)Phase 3NDA planned/submission stated for H1 2026; pediatric registrational trial initiatedUSEUChronic HypoparathyroidismPhase 2NIH investigator-initiated study; Phase 3 planned in 2026
- InfigratinibFGFR3 / Small Molecule / Skeletal dysplasia; genetic diseaseAchondroplasiaPhase 3PROPEL 3 registrational study; infant/toddler study enrollingUSEUHypochondroplasiaPhase 2ACCEL 2/3 Phase 2 portion dosed; data expected H2 2026
- BBP-812BBP-812 / ASPA / Gene Therapy / Genetic disease; neurologyCanavan DiseaseInvestigational AAV gene therapy
Latest news20 items
All newsBridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
Presentation / Abstract • Phase 3